Cardio-Oncology: Lessons Learned
Dr. Abbate defines CTRCD as a decrease in left ventricular ejection fraction (LVEF) of over 10 percentage points to below 50%, regardless of symptoms. This definition encompasses both symptomatic and asymptomatic cases, as well as diastolic dysfunction. With increasing cancer survivorship, CTRCD has become a critical concern, particularly given the potential for delayed cardiac toxicity.